About 20% more patients started Syndax's leukemia drug in Q3 than Q2; new data are expected in Q4.
Syndax Pharmaceuticals reported Q3 2026 revenue of $60.7M for Revuforj and $67.4M for Niktimvo, with Revuforj showing 90% YoY growth. The company expects new data on Revuforj in Q4 2026 from multiple clinical trials and real-world studies. Syndax plans to initiate the RAVEN trial in Q4 2026 and the MenTain trial in Q1 2027. The company will host a conference call today at 4:30 p.m. ET.
How this was made
The 30-second read
Why it matters
The Q3 earnings release provides the first public disclosure of significant revenue growth and patient uptake, setting the stage for upcoming trial data later in the year.
Market read
First‑time earnings data with strong growth metrics, likely to move the stock and influence the AML biotech niche.
What to watch
Pending regulatory approvals and the timing of upcoming trial readouts could temper upside.
Background
Syndax Pharmaceuticals (Nasdaq: SNDX) is a commercial‑stage biotech focused on menin inhibitor therapies for acute leukemia.
Ticker impact
Syndax reported Q3 2026 net revenue of $60.7M for Revuforj and $67.4M for Niktimvo, a 90% YoY increase for Revuforj and 47% YoY for Niktimvo, plus 20% patient growth quarter‑over‑quarter.
likely upside as the market prices in robust sales growth and upcoming data milestones.
Revenue beat expectations and double‑digit growth in a niche oncology market typically drive short‑term buying interest.
Market effects
Highlights strength in the AML/oncology biotech sector and may boost peer valuations.
U.S. biotech investors could see a rally in related small‑cap stocks.
Positive data could influence global oncology pipeline funding and partnership activity.
Counterpoint
Rapid revenue growth may be unsustainable if competition intensifies or reimbursement slows.
Key entities
- companySyndax Pharmaceuticals
Biopharma developing menin inhibitor Revuforj (revumenib) and co‑commercializing Niktimvo.
